Literature DB >> 12904482

Group III metabotropic glutamate receptor-mediated modulation of the striatopallidal synapse.

Ornella Valenti1, Michael J Marino, Marion Wittmann, Edward Lis, Anthony G DiLella, Gene G Kinney, P Jeffrey Conn.   

Abstract

The globus pallidus (GP) is a key GABAergic nucleus in the basal ganglia (BG). The predominant input to the GP is an inhibitory striatal projection that forms the first synapse in the indirect pathway. The GP GABAergic neurons project to the subthalamic nucleus, providing an inhibitory control of these glutamatergic cells. Given its place within the BG circuit, it is not surprising that alterations in GP firing pattern are postulated to play a role in both normal and pathological motor behavior. Because the inhibitory striatal input to the GP may play an important role in shaping these firing patterns, we set out to determine the role that the group III metabotropic glutamate receptors (GluRs) play in modulating transmission at the striatopallidal synapse. In rat midbrain slices, electrical stimulation of the striatum evoked GABA(A)-mediated IPSCs recorded in all three types of GP neurons. The group III mGluR-selective agonist L-(+)-2-amino-4-phosphonobutyric acid (L-AP4) inhibited these IPSCs through a presynaptic mechanism of action. L-AP4 exhibited high potency and a pharmacological profile consistent with mediation by mGluR4. Furthermore, the effect of L-AP4 on striatopallidal transmission was absent in mGluR4 knock-out mice, providing convincing evidence that mGluR4 mediates this effect. The finding that mGluR4 may selectively modulate striatopallidal transmission raises the interesting possibility that activation of mGluR4 could decrease the excessive inhibition of the GP that has been postulated to occur in Parkinson's disease. Consistent with this, we find that intracerebroventricular injections of L-AP4 produce therapeutic benefit in both acute and chronic rodent models of Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12904482      PMCID: PMC6740663     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  57 in total

1.  Re-exploration of the PHCCC Scaffold: Discovery of Improved Positive Allosteric Modulators of mGluR4.

Authors:  Richard Williams; Ya Zhou; Colleen M Niswender; Qingwei Luo; P Jeffrey Conn; Craig W Lindsley; Corey R Hopkins
Journal:  ACS Chem Neurosci       Date:  2010-06-16       Impact factor: 4.418

Review 2.  Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.

Authors:  Yoland Smith; Thomas Wichmann; Stewart A Factor; Mahlon R DeLong
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

3.  Symptomatic and neuroprotective effects following activation of nigral group III metabotropic glutamate receptors in rodent models of Parkinson's disease.

Authors:  P J Austin; M J Betts; M Broadstock; M J O'Neill; S N Mitchell; S Duty
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

4.  The Metabotropic Glutamate Receptor 4 Positive Allosteric Modulator ADX88178 Inhibits Inflammatory Responses in Primary Microglia.

Authors:  Ranjani Ponnazhagan; Ashley S Harms; Aaron D Thome; Asta Jurkuvenaite; Rocco Gogliotti; Colleen M Niswender; P Jeffrey Conn; David G Standaert
Journal:  J Neuroimmune Pharmacol       Date:  2016-02-12       Impact factor: 4.147

Review 5.  The external globus pallidus: progress and perspectives.

Authors:  Daniel J Hegeman; Ellie S Hong; Vivian M Hernández; C Savio Chan
Journal:  Eur J Neurosci       Date:  2016-03-28       Impact factor: 3.386

Review 6.  Glutamate and GABA receptors and transporters in the basal ganglia: what does their subsynaptic localization reveal about their function?

Authors:  A Galvan; M Kuwajima; Y Smith
Journal:  Neuroscience       Date:  2006-10-23       Impact factor: 3.590

7.  Activation of group III metabotropic glutamate receptors in selected regions of the basal ganglia alleviates akinesia in the reserpine-treated rat.

Authors:  Nicholas MacInnes; Marcus J Messenger; Susan Duty
Journal:  Br J Pharmacol       Date:  2003-11-03       Impact factor: 8.739

8.  Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment.

Authors:  Michael J Marino; David L Williams; Julie A O'Brien; Ornella Valenti; Terrence P McDonald; Michelle K Clements; Ruiping Wang; Anthony G DiLella; J Fred Hess; Gene G Kinney; P Jeffrey Conn
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-30       Impact factor: 11.205

Review 9.  Therapeutic potential of targeting glutamate receptors in Parkinson's disease.

Authors:  Clare Finlay; Susan Duty
Journal:  J Neural Transm (Vienna)       Date:  2014-02-21       Impact factor: 3.575

10.  Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4.

Authors:  Colleen M Niswender; Kari A Johnson; C David Weaver; Carrie K Jones; Zixiu Xiang; Qingwei Luo; Alice L Rodriguez; Joy E Marlo; Tomas de Paulis; Analisa D Thompson; Emily L Days; Tasha Nalywajko; Cheryl A Austin; Michael Baxter Williams; Jennifer E Ayala; Richard Williams; Craig W Lindsley; P Jeffrey Conn
Journal:  Mol Pharmacol       Date:  2008-07-29       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.